Lexaria Bioscience Corp
LEXX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.71M
Close$
$-1.66
127.2% downside
Current Fair Value
127.2% downsideOvervalued by 127.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.71 Million |
|---|---|
| Enterprise Value | $5.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.9 |
| Beta | 0.34 |
| Outstanding Shares | 1,653,728 |
Return
| Return on Equity | -163.18% |
|---|---|
| Return on Assets | -161.71% |
| Return on Invested Capital | -175.94% |
Valuation & Multiples
| P/E Ratio | -0.99 |
|---|---|
| PEG | 2.09 |
| Price to Sales | - |
| Price to Book Ratio | 3.06 |
| Enterprise Value to Revenue | 27.42 |
| Enterprise Value to EBIT | -0.69 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 13, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.10%▼ 1.86% |
|---|---|
| Total Invested | $1.17M▲ 10.80% |
| Investors Holding | 28▲ 7.00% |
ESG Score
No data
About Lexaria Bioscience Corp
3 employeesLexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness...